Edwards Lifesciences (EW) stock faces a downgrade at Wolfe due to concerns over its TAVR market prospects. Read more here.

Wedgewood Partners, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the letter ...

Citi analyst Joanne Wuensch maintained a Buy rating on Edwards Lifesciences (EW – Research Report) today. The company’s shares closed yesterday ...

Edwards Lifesciences Corp. engages in the patient ... Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter ...

Capital Investment Advisors LLC lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.4% during the fourth quarter, according to its most recent disclosure with the ...

Harbor Capital Advisors Inc. boosted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.5% during the 4th quarter, according to its most recent disclosure with the ...

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...

The US Supreme Court rejected a case asking the justices to interpret a patent-infringement safe-harbor provision in a ...

Edwards Lifesciences Corporation (NYSE:EW) offers products and technologies for structural heart disease and critical ... s flagship transcatheter aortic valve replacement (TAVR) franchise slowed ...

We continued to make significant investments in healthcare technologies in the domestic and international markets, even in a ...